Production of erythropoietin by endogenous gene activation
CA 2298015 C · Owner: Stern, Anne · Inventors: Stern, Anne; Honold, Konrad; Koll, Hans
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to human cells which are capable on the basis of an , activation of the endogenic human EPO gene, of producing EPO in a sufficient amount and purity to make , possible a cost-effective production of human EPO as a pharmaceutical preparation. The , invention furthermore relates to a method for the preparation of such human EPO-producing cells, DNA constructs for the activation of the endogenic EPO in human cells, and method for the large technical production of EPO in human cells.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 22, 1998 and granted January 27, 2015. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 22, 2018.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 22, 2020.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.